Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line therapy in metastatic breast cancer: A retrospective analysis

Tumori

Volumn 95, Issue 4, 2009, Pages 422-426

  Livi, Lorenzo ^a   Meattini, Icro ^a   Cardillo, Carla De Luca ^a   Mangoni, Monica ^a   Greto, Daniela ^a   Petrucci, Alessia ^a   Rampini, Andrea ^a   Bruni, Alessio ^a   Galardi, Alessandra ^a   Cataliotti, Luigi ^a   Biti, Giampaolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Breast cancer; Docetaxel; Non pegylated doxorubicin

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DEXCHLORPHENIRAMINE MALEATE; DOCETAXEL; DOXORUBICIN; PREDNISONE;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIMARY HEALTH CARE; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

EID: 70350040943     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500402     Document Type: Article

References (25)

1. Bergh J, Jönsson PE, Glimelius B, Nygren P: A systematic overview of chemotherapy effects in breast cancer. Acta Oncol, 40: 253-281, 2001. (Pubitemid 32590835)
2. Hamilton A, Hortobagyi G: Chemotherapy: what progress in the last 5 years? J Clin Oncol, 23: 1760-2175, 2005.
3. Lord S, Ghersi D, Gattellari M, Wortley S, Wilcken N, Simes J: Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev, 4: CD003367, 2004.
4. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol, 14: 2197-2205, 1996.
5. Valero V, Hortobagyi GN: Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer? J Clin Oncol, 21: 959-962, 2003. (Pubitemid 46594120)
6. Sledge GW: The continuing problem of cardiac toxicity. Semin Oncol, 28(4 Suppl 12): 1, 2001.
7. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, Canetta R, Castellani R, Villa E, Gallagher CG, von Melchner H, Hayat M, Ribaud P, De Wasch G, Mattsson W, Heinz R, Waldner R, Kolaric K, Buehner R, Ten Bokkel-Huyninck W, Perevodchikova NI, Manziuk LA, Senn HJ, Mayr AC: Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep, 63: 827-834, 1979.
8. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 91: 710-717, 1979. (Pubitemid 10218041)
9. Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz PE, Berger HJ, Setaro J, Surkin L, et al: Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med, 82: 1109-1118, 1987. (Pubitemid 18101522)
10. Tardi PG, Boman NL, Cullis PR: Liposomal doxorubicin. J Drug Target, 4: 129-140, 1996.
11. Dando TM, Keating GM: Liposomal doxorubicin: a review of its use in metastatic breast cancer and potential in non-Hodgkin lymphoma. Am J Cancer, 4: 193-206, 2005.
12. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol, 19: 1444-1454, 2001. (Pubitemid 32202552)
13. Harris L, Batist G, Beit R, Rovira D, Navari R, Azarnia N, Welles L, Winer E; TLC D-99 Study Group: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast cancer. Cancer, 94: 25-36, 2002.
14. Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P: Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis. Anti-Cancer Drugs, 17: 587-595, 2006. (Pubitemid 44309976)
15. van Dalen EC, Michiels EMC, Caron HN, Kremer LCM: Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev, 4: CD005006, 2006.
16. World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO, Geneva, 1979.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
18. Chan S, Davidson N, Juozaitye E, Erdkamp F, Pluzanska A, Azarnia N, Lee LW: Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for therapy for metastatic breast cancer. Ann Oncol, 15: 1527-1534, 2004. (Pubitemid 39409744)
19. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line therapy in metastatic breast cancer. The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase II trial. J Clin Oncol, 20: 3114-3121, 2002. (Pubitemid 34791101)
20. Luck H, Thomssen C, Untch M, Kuhn W, Eidtmam H, Du Bois A: Multicentric Phase III Study in First Line Treatment of Advanced Metastatic Breast Cancer (ABC). Epirubicin/paclitaxel (ET) vs epirubicin/cyclophosphamide (EC). A study of the Ago Breast Cancer Group. 2000 ASCO Annual Meeting. Proc Am Soc Clin Oncol, 19: 2000 (abstract 2080).
21. Carmichael J: UKCCCR Trial of Epirubicin and Cyclophosphamide (EC) Vs. Epirubicin and Taxol® in the First-Line Treatment of Women with Metastatic Breast Cancer (MBC). 2001 ASCO annual Meeting. Proc Am Soc Clin Oncol, 20: 2001 (abstract 84).
22. van Dalen EC, Caron HN, Dickinson HO, Kremer LC: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, 16: CD003917, 2008.
23. Marty M, Espié M, Llombart A, Monnier A, Rapoport BL, Stahalova V; Dexrazoxane Study Group: Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol, 17: 614-622, 2006.
24. Del Barco S, Colomer R, Calvo L, Tusquets I, Adrover E, Sánchez P, Rifà J, De la Haba J, Virizuela JA: Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial. Breast Cancer Res Treat, 116 (2): 351-359, 2009.
25. Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S, Schulz CO, Dieing A, Wischnewsky MB, Hauptmann S, Elling D, Possinger K, Flath B: Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol, 16: 1624-1631, 2005. (Pubitemid 41510136)